Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Swallowing and quality of life after prophylactic versus reactive PEG in advanced head and neck cancer treated with chemoradiotherapy
2019-001077-87Phase 3Active
- Sponsor
- Institut Jules Bordet
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in head and neck cancer (HNC) (2 arms), sponsored by Institut Jules Bordet. Primary endpoint: Global MDADI score at 6 months after end of treatment. Started Jun 2019; status: active.
02
Drugs
cisplatin
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on 2019-001077-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001077-87.